NCT07261683 2025-12-19Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian CancerObstetrics & Gynecology Hospital of Fudan UniversityPhase 2 Recruiting20 enrolled